214 related articles for article (PubMed ID: 15694012)
1. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
Price N; Belani C
Clin Lung Cancer; 2005 Jan; 6(4):214-6. PubMed ID: 15694012
[No Abstract] [Full Text] [Related]
2. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
[No Abstract] [Full Text] [Related]
3. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Stinchcombe TE; Ramalingam SS
Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
[No Abstract] [Full Text] [Related]
4. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
Belani CP; Ramalingam S
Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
[No Abstract] [Full Text] [Related]
5. Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
Saijo N
Nat Rev Clin Oncol; 2010 Nov; 7(11):618-9. PubMed ID: 20981125
[No Abstract] [Full Text] [Related]
6. Updated data from the Iressa survival in lung cancer trial.
Tyagi P
Clin Lung Cancer; 2005 May; 6(6):340-2. PubMed ID: 15943893
[No Abstract] [Full Text] [Related]
7. Role of tyrosine kinase inhibitors in lung cancer.
Ansari J; Palmer DH; Rea DW; Hussain SA
Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
[TBL] [Abstract][Full Text] [Related]
8. ZD1839 (Iressa) in non-small cell lung cancer.
Herbst RS; Kies MS
Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
[TBL] [Abstract][Full Text] [Related]
9. [Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].
Madelaine J; Cadranel J; Zalcman G
Rev Mal Respir; 2004 Nov; 21(5 Pt 1):881-5. PubMed ID: 15622331
[No Abstract] [Full Text] [Related]
10. Commentary on ZD1839 (Iressa) in non small cell lung cancer.
Ranson M; Thatcher N
Lung Cancer; 2003 Apr; 40(1):77-8. PubMed ID: 12660010
[No Abstract] [Full Text] [Related]
11. Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recents results and further strategies.
Manegold C
Adv Exp Med Biol; 2003; 532():247-52. PubMed ID: 12908563
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib (Iressa) trials in non-small cell lung cancer.
Johnson DH
Lung Cancer; 2003 Aug; 41 Suppl 1():S23-8. PubMed ID: 12867059
[TBL] [Abstract][Full Text] [Related]
13. [Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
Shimizu J; Horio Y; Mitsudomi T
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1879-85. PubMed ID: 16282720
[TBL] [Abstract][Full Text] [Related]
14. EGFR pharmacogenomics: the story continues to mutate and evolve.
Desai AA; Ratain MJ
Am J Pharmacogenomics; 2005; 5(2):137-9. PubMed ID: 15813677
[No Abstract] [Full Text] [Related]
15. The miracle of Iressa.
Chabner BA
Oncologist; 2004; 9(3):245-6. PubMed ID: 15169979
[No Abstract] [Full Text] [Related]
16. Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.
Dancey JE
Cancer Cell; 2004 May; 5(5):411-5. PubMed ID: 15144948
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.
Sridhar SS; Seymour L; Shepherd FA
Lancet Oncol; 2003 Jul; 4(7):397-406. PubMed ID: 12850190
[TBL] [Abstract][Full Text] [Related]
18. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
[TBL] [Abstract][Full Text] [Related]
19. Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.
Hishida T; Nagai K; Mitsudomi T; Yokoi K; Kondo H; Horinouchi H; Akiyama H; Nagayasu T; Tsuboi M;
J Thorac Cardiovasc Surg; 2010 Nov; 140(5):e69-71. PubMed ID: 20674944
[No Abstract] [Full Text] [Related]
20. Molecular selection trumps clinical selection.
Shepherd FA
J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
[No Abstract] [Full Text] [Related]
[Next] [New Search]
